Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2016 by Dana-Farber Cancer Institute
Sponsor:
Collaborators:
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
GlaxoSmithKline
Novartis
Information provided by (Responsible Party):
Joaquim Bellmunt, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01184326
First received: August 17, 2010
Last updated: March 16, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2017
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)